Smith & Nephew SNATS (SNN)
(Delayed Data from NYSE)
$30.96 USD
-0.55 (-1.75%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $30.97 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$30.96 USD
-0.55 (-1.75%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $30.97 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
Is Britain Headed for a Soft Brexit? 5 Picks
by Swarup Gupta
Following May's fresh legislative defeat, Britain could exit the EU while retaining access to its common market.
Smith & Nephew (SNN): Moving Average Crossover Alert
by Zacks Equity Research
Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Orthopedic Device Market Gains Momentum: 3 Stocks in Focus
by Zacks Equity Research
The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.
Medical Device Industry Outlook - February 2018
by Zacks Equity Research
Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.
MedTech Tax Resumes in 2018, 3 Stocks to Suffer
by Zacks Equity Research
Sectors that are likely to be hampered the most by the re-imposition of the medical device tax are X-ray and MRI machines, surgical instruments and pacemakers.
Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm
by Zacks Equity Research
Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew
MedTech Industry Outlook - October 2017
by Zacks Equity Research
The Trump administration has not come up with any concrete plan to replace the MedTech tax as of yet.
Graham-Cassidy Fail Shines Spotlight on 3 Top Dividend Stocks
by Zacks Equity Research
Zeroing in on dividend stocks with a solid Zacks Rank is a great way to increase the chances of beating volatile market conditions while ensuring a steady stream of cash flow. Here are three top picks in the MedTech space.
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill
by Zacks Equity Research
The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.
Republicans Take Last Shot at Obamacare: 5 MedTech Stocks to Buy
by Zacks Equity Research
The fate of Obamacare will be decided on Sep. 30. No matter what the future holds, the day will provide investors a clear picture of where the MedTech industry is headed.
MedTech Hangs in the Balance as Obamacare Skinny Repeal Fails
by Zacks Equity Research
Any retention or repeal of Obamacare will actually create a vicious circle within the MedTech sector.
5 British Stocks to Profit From a Weak Pound Sterling
by Swarup Gupta
Companies exporting products and services stand to benefit from a weaker pound.
3 MedTech Stocks Set to Rally in the Second Half
by Zacks Equity Research
The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.
Anika (ANIK) Grows in Orthopedic Medicines on Positive Data
by Zacks Equity Research
Anika Therapeutics' (ANIK) data shows HYALOFAST as an effective treatment option for cartilage lesions, suitable to all age groups.
Medical Product Stocks Q1 Earnings Slated on May 5: VWR, SNN
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 5.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
Emerging market expansion, positive demographic trends and new product innovation have been the vital forces behind the continued uptrend of the sector's performance.
MedTech Industry Stock Outlook - March 2015
by Zacks Equity Research
Emerging market expansion, positive demographic trends and new product innovation have been the vital forces behind the continued uptrend of the sector's performance.
MedTech M&As Continue Regardless of Tax Scenarios
by Zacks Equity Research
MedTech stalwarts are not expected to shy away from hostile acquisition bids this year.